Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 5
2008 12
2009 7
2010 9
2011 12
2012 6
2013 11
2014 30
2015 28
2016 30
2017 47
2018 33
2019 44
2020 71
2021 100
2022 95
2023 103
2024 76
2025 74
2026 59

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

738 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. Among authors: herrmann k. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: herrmann k. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Free PMC article. Clinical Trial.
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Singh S, et al. Among authors: herrmann k. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851203 Clinical Trial.
Radiotheranostics: a roadmap for future development.
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Herrmann K, et al. Lancet Oncol. 2020 Mar;21(3):e146-e156. doi: 10.1016/S1470-2045(19)30821-6. Lancet Oncol. 2020. PMID: 32135118 Free PMC article. Review.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. Fendler WP, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. doi: 10.1007/s00259-022-06089-w. Epub 2023 Jan 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 36604326 Free PMC article.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Seifert R, et al. Among authors: herrmann k. Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17. Eur Urol. 2023. PMID: 36935345 Free article. Review.
The molecular blueprint of targeted radionuclide therapy.
Primac I, Tabury K, Tasdogan A, Baatout S, Herrmann K. Primac I, et al. Among authors: herrmann k. Nat Rev Clin Oncol. 2025 Nov;22(11):869-894. doi: 10.1038/s41571-025-01069-z. Epub 2025 Sep 9. Nat Rev Clin Oncol. 2025. PMID: 40926013 Review.
EANM practice guideline for quantitative SPECT-CT.
Dickson JC, Armstrong IS, Gabiña PM, Denis-Bacelar AM, Krizsan AK, Gear JM, Van den Wyngaert T, de Geus-Oei LF, Herrmann K. Dickson JC, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):980-995. doi: 10.1007/s00259-022-06028-9. Epub 2022 Dec 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 36469107 Free PMC article.
Radiotherapy and theranostics: a Lancet Oncology Commission.
Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, Li JJ, Mueller M, Aggarwal A, Al-Ibraheem A, Alkhatib S, Atun R, Bello A, Berger D, Delgado Bolton RC, Buatti JM, Burt G, Bjelac OC, Cordero-Mendez L, Dosanjh M, Eichler T, Fidarova E, Gondhowiardjo S, Gospodarowicz M, Grover S, Hande V, Harsdorf-Enderndorf E, Herrmann K, Hofman MS, Holmberg O, Jaffray D, Knoll P, Kunikowska J, Lewis JS, Lievens Y, Mikhail-Lette M, Ostwald D, Palta JR, Peristeris P, Rosa AA, Salem SA, Dos Santos MA, Sathekge MM, Shrivastava SK, Titovich E, Urbain JL, Vanderpuye V, Wahl RL, Yu JS, Zaghloul MS, Zhu H, Scott AM. Abdel-Wahab M, et al. Among authors: herrmann k. Lancet Oncol. 2024 Nov;25(11):e545-e580. doi: 10.1016/S1470-2045(24)00407-8. Epub 2024 Sep 30. Lancet Oncol. 2024. PMID: 39362232 Review.
738 results